Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Darolutamide Approved by the FDA for Non-Metastatic Castration-Resistant Prostate Cancer

By: Sarah Jackson
Posted: Thursday, August 1, 2019

On July 30, 2019, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for non-metastatic castration-resistant prostate cancer.

Approval was based on ARAMIS (ClinicalTrials.gov identifier NCT02200614), a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to receive either 600 mg darolutamide orally twice daily (n = 955) or matching placebo (n = 554). All patients received a gonadotropin-releasing hormone analog concurrently or had a previous bilateral orchiectomy. Twelve patients with previous seizure histories were treated on the darolutamide arm.

The primary endpoint was metastasis free survival, defined as the time from randomization to first evidence of distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first. The median metastasis free survival was 40.4 months for patients treated with darolutamide compared with 18.4 months for those receiving placebo. Overall survival data were not mature.

The most common adverse reactions (≥ 2%) in patients who received darolutamide were fatigue, pain in extremity, and rash. Ischemic heart disease (4.3%) and heart failure (2.1%) were more common on the darolutamide arm. The seizure incidence was similar on the two arms (0.2%).

The recommended darolutamide dose is 600 mg (two 300 mg tablets) administered orally twice daily with food. Patients should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.